Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Nov 26;62(12):e01686-18.
doi: 10.1128/AAC.01686-18. Print 2018 Dec.

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus

Tim R Cressey  1   2   3 , Linda Harrison  4 , Jullapong Achalapong  5 , Prateep Kanjanavikai  6 , Orada Patamasingh Na Ayudhaya  7 , Prateung Liampongsabuddhi  8 , Thitiporn Siriwachirachai  9 , Chaiwat Putiyanun  10 , Pornnapa Suriyachai  11 , Camlin Tierney  4 , Nicolas Salvadori  12 , Dujrudee Chinwong  13 , Luc Decker  14 , Yardpiroon Tawon  12 , Trudy V Murphy  15 , Nicole Ngo-Giang-Huong  12   2   14 , George K Siberry  16 , Gonzague Jourdain  12   2   13 ; iTAP Study Team
Collaborators, Affiliations
Randomized Controlled Trial

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus

Tim R Cressey et al. Antimicrob Agents Chemother. .

Abstract

We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.

Keywords: hepatitis B virus; pharmacokinetics; pregnancy; tenofovir.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Tenofovir plasma concentration-time curves for the average woman during pregnancy (closed diamonds) and postpartum (open diamonds), derived using the final population pharmacokinetic model. Conc., concentration.
See this image and copyright information in PMC

References

    1. World Health Organization. 2017. Global hepatitis report, 2017. World Health Organization, Geneva, Switzerland: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng....
    1. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97–107. doi:10.1046/j.1365-2893.2003.00487.x. - DOI - PubMed
    1. Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. 2013. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 59:24–30. doi:10.1016/j.jhep.2013.02.015. - DOI - PubMed
    1. European Association for the Study of the Liver. 2017. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67:370–398. doi:10.1016/j.jhep.2017.03.021. - DOI - PubMed
    1. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. 2018. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560–1599. doi:10.1002/hep.29800. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources